OrbiMed

OrbiMed Advisors LLC, formerly Mehta & Isaly, is a private investment firm based in New York City, specialising in the healthcare and biotechnology sectors. It was established in 1998 by Samuel Isaly, Michael Sheffery, and Arvind Desai. OrbiMed's focus is on public and private equity, venture capital, and private credit. The firm manages approximately $18 billion in assets as of March 2024 and employs 112 professionals.

The company initially began as Mehta & Isaly in 1989, founded by S.G. Warburg pharmaceutical analysts Viren Mehta and Samuel Isaly. In 1998, the firm split into two entities, with Isaly forming OrbiMed Advisors. OrbiMed made its first venture capital investment in 1993 and expanded globally, opening offices in Shanghai, Mumbai, and Herzliya. In 2017, Samuel Isaly stepped down following allegations of misconduct.

OrbiMed invests globally in various healthcare fields, including biopharmaceuticals, medical devices, diagnostics, and healthcare services. It supports companies at all stages of development, from start-ups to large corporations, offering tailored financing solutions. Its portfolio includes notable investments such as AbCellera Biologics, Intercept Pharmaceuticals, and Natera.

The firm operates across multiple regions, including North America, Europe, and Asia, and employs a team of over 130 professionals with expertise in life sciences, medicine, and finance. OrbiMed is known for its flexible investment strategies, which include private equity, private credit, and public equity funds.

OrbiMed has contributed to the development of over 60 healthcare therapies and has backed more than 90 life sciences start-ups. The firm is committed to responsible investing and has invested over $2 billion in healthcare initiatives in developing countries. The firm’s offices are located in major global markets, including New York, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and London.

OrbiMed Advisors LLC, originally known as Mehta & Isaly, was founded in 1989 by Viren Mehta and Samuel Isaly, who were pharmaceutical analysts at S.G. Warburg. Mehta & Isaly was a money-management and research firm focused on the healthcare industry. 

The firm made its first venture capital investment in 1993. In 1998, the company split into two separate entities: Mehta formed Mehta Partners, while Isaly established OrbiMed Advisors, focusing on investments in the healthcare and biotechnology sectors.

In 2000, OrbiMed launched its first dedicated venture capital fund, marking a significant step in its investment strategy. By 2007, OrbiMed expanded its global presence by opening offices in San Francisco, Shanghai, and later Mumbai, strengthening its reach in the United States and Asia. 

In 2010, OrbiMed further extended its footprint by establishing an office in Herzliya, Israel, to support its investments in the Middle East.

In 2011, OrbiMed launched its first dedicated royalty/credit fund, diversifying its investment approach to include non-dilutive capital solutions for healthcare companies.

By 2015, the firm had grown significantly, hiring its 100th employee. 

In 2017, OrbiMed expanded to Hong Kong, enhancing its presence in Asia. In the same year, Samuel Isaly stepped down as managing partner due to allegations of misconduct raised by former employees.

OrbiMed continued to grow, and in 2023, it opened an office in London, reinforcing its position in the European market.

As of March 2024, OrbiMed manages approximately $18 billion in assets and employs 112 professionals. The firm has invested in over 90 life sciences start-ups and contributed to the development of more than 60 healthcare therapies. It operates in key global markets with offices in New York, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and London. OrbiMed remains committed to supporting companies engaged in healthcare innovation, focusing on public equity, private equity, and private credit/royalty investments.

OrbiMed’s recent activities include raising over $4.3 billion across private investment funds and expanding its portfolio with significant investments in companies engaged in biopharmaceuticals, medical technologies, diagnostics, and healthcare services.

OrbiMed's investment criteria focus on the healthcare and biotechnology sectors, targeting companies at various stages of development, from early-stage start-ups to large multinational corporations. The firm aims to invest in businesses that are involved in biopharmaceuticals, medical devices, diagnostics, healthcare services, and related areas of healthcare innovation.

Key Investment Strategies:

• Private Equity: OrbiMed invests in private companies at various stages, including start-ups, growth-stage companies, and more mature firms. The firm often acts as a lead investor, working closely with portfolio companies to build them into market leaders. OrbiMed's private equity investments are global, covering regions like North America, Europe, and Asia.
• Private Credit/Royalty: OrbiMed provides structured debt and royalty-based financing to healthcare companies that are in the commercial stage of their development. This allows companies to raise capital without diluting ownership while monetising their royalty streams. This form of investment is beneficial for companies seeking flexible financing options.
• Public Equity: OrbiMed manages various public equity funds, including long/short event-driven funds and closed-end investment trusts. These funds invest in publicly traded healthcare companies across different sectors, such as biopharmaceuticals, medical devices, healthcare services, and more.

OrbiMed looks for companies that focus on responsible, sustainable growth and aim to build long-term shareholder value. The firm is particularly interested in businesses that show potential for healthcare innovation and can address global health challenges. OrbiMed has also committed over $2 billion to healthcare initiatives in developing countries.

The firm has backed over 90 life sciences start-ups and contributed to the successful development of more than 60 healthcare therapies. 

OrbiMed’s core values are centred around promoting healthcare innovation, responsible investing, and long-term sustainable growth. The firm is committed to making impactful investments that not only generate returns for shareholders but also contribute positively to the global healthcare landscape.

Key Values:

• Healthcare Innovation: OrbiMed places a strong emphasis on investing in companies that push the boundaries of science and medicine. The firm seeks out businesses that are developing breakthrough therapies, medical technologies, diagnostics, and healthcare services. OrbiMed has been instrumental in supporting over 60 new healthcare therapies through its venture capital portfolio, demonstrating its commitment to innovation.
• Global Reach and Expertise: With offices in major markets across North America, Europe, Asia, and the Middle East, OrbiMed brings a global perspective to its investments. The firm’s team of over 130 professionals includes experts in life sciences, medicine, and finance, enabling a collaborative and informed investment approach. This global presence allows OrbiMed to scout for innovations worldwide and support companies in different regions.
• Responsible Investing: OrbiMed is committed to responsible investing and sustainable growth. The firm seeks to invest in companies that align with its values of ethical business practices and long-term value creation. OrbiMed’s Responsible Investing Policy outlines its focus on building companies that contribute positively to healthcare outcomes and society as a whole.
• Impact in Developing Countries: OrbiMed has committed over $2 billion to healthcare projects in developing countries. This includes investments in maternal care hospitals in India and dialysis centres in China, showcasing the firm’s dedication to addressing global healthcare challenges and improving access to care in underserved regions.

OrbiMed’s mission is to support and invest in innovative healthcare companies that improve global health outcomes. The firm seeks to identify and fund businesses developing breakthrough therapies, medical devices, diagnostics, and healthcare services. OrbiMed aims to provide these companies with the necessary capital and strategic guidance to help them succeed and grow. The firm is committed to responsible investing and sustainable growth, focusing on long-term value creation for its investors and society. Through its global presence and expertise, OrbiMed strives to make a positive impact on healthcare worldwide, enhancing patient care and advancing medical science.

Here is a detailed portfolio of OrbiMed's investments, including a brief description of each company:

• AbCellera Biologics: A biotechnology company specialising in the discovery of therapeutic antibodies through innovative technology platforms.
• Acceleron Pharma: Focuses on the development of protein therapeutics to treat serious and rare diseases.
• Ambit Biosciences: Develops small molecule therapeutics for the treatment of cancer and inflammatory diseases.
• California Institute for Quantitative Biosciences: Supports interdisciplinary research in biological sciences, focusing on innovative healthcare solutions.
• Cynapsus Therapeutics: A specialty pharmaceutical company developing treatments for Parkinson's disease.
• DFINE, Inc.: A medical device company that offers minimally invasive therapies for the treatment of spinal disorders.
• Gelesis: Develops innovative therapies to treat obesity and other chronic diseases related to the gastrointestinal tract.
• Intercept Pharmaceuticals: Focuses on developing novel therapeutics to treat progressive non-viral liver diseases.
• Natera: Specialises in genetic testing and diagnostics, providing early insight into genetic conditions and helping to improve patient outcomes.
• OmniGuide: Develops advanced surgical instruments for minimally invasive surgeries, enhancing precision and patient safety.
• TigerConnect: A secure messaging platform designed to enhance communication among healthcare teams, improving patient care and workflow efficiency.
• Acelyrin: A biopharmaceutical company dedicated to developing transformative medicines for patients with serious and chronic diseases.
• Acutus Medical: Provides electrophysiological solutions to improve the diagnosis and treatment of complex arrhythmias.
• Adaptive Biotechnologies: Uses immune system data to develop novel diagnostics and therapeutics for various diseases.
• ADARx Pharmaceuticals: Focuses on RNA-targeted therapies for treating rare genetic and other serious diseases.
• Adela: A healthcare company that develops blood-based cancer detection and monitoring technologies.
• Adicet Bio: Develops off-the-shelf gamma delta T cell therapies for cancer treatment.
• Advanced Enzymes: Produces enzyme-based products for various industries, including pharmaceuticals and food processing.
• AER Therapeutics: A biopharma company advancing treatments for respiratory diseases by targeting the lung’s airways.
• Aerin Medical: Develops minimally invasive solutions to treat nasal airway disorders and improve breathing.
• AIMS: Specialises in artificial intelligence solutions for improving patient care and operational efficiency in healthcare settings.
• AK Medical: Provides orthopaedic implant products and services, primarily in the Chinese healthcare market.
• Aliad Therapeutics: Focuses on developing targeted therapies for cancer patients using novel drug delivery technologies.
• Alpheus Medical: Develops non-invasive therapies for brain tumours using focused ultrasound technology.
• Alterome Therapeutics: Targets genetic alterations in cancer to create innovative and effective cancer treatments.
• Amolyt Pharma: Focuses on the development of therapeutic peptides for rare endocrine and metabolic diseases.
• AnchorDx: Develops precision oncology diagnostics for the early detection and treatment of cancer.
• Angitia Biopharmaceuticals: A biopharma company working on innovative therapies for diseases related to fibrosis and inflammation.
• Apogee Therapeutics: Develops novel antibody therapies to treat inflammatory and autoimmune diseases.
• ArriVent Biopharma: Focuses on developing oncology therapeutics through collaborations and innovative research.
• ARS Pharma: Develops products for severe allergic reactions and other life-threatening conditions.
• Aspen Neuroscience: Pioneers personalised cell therapy treatments for Parkinson’s disease.
• Avenzo Therapeutics: Develops next-generation cancer therapies using precision medicine approaches.
• Avita Medical: Specialises in regenerative medicine, offering treatments for skin conditions and burns.
• Avitide: Provides innovative solutions for biopharmaceutical purification processes.
• Azura Ophthalmics: Develops ophthalmic therapies to treat meibomian gland dysfunction and other eye conditions.
• Baili Pharmaceuticals: Focuses on the development and manufacturing of generic drugs for various therapeutic areas.
• Beijing Star Sports Medicine: Provides medical products and services for sports injury prevention and rehabilitation.
• Binx Health: Offers diagnostic solutions for sexually transmitted infections, providing quick and accurate results.
• BioMX: A biotechnology company developing microbiome-based treatments for various health conditions.
• BioNova Pharmaceuticals: Focuses on the research and development of novel oncology therapies.
• BlossomHill Therapeutics: Develops small molecule drugs to treat autoimmune and cancer diseases.
• MobileODT: Utilises AI technology for cervical cancer screening and diagnosis in low-resource settings.
• Bonovo Orthopedics: A leading provider of orthopaedic products in China, specialising in implants and surgical instruments.
• CalciMedica: Focuses on developing therapies that target calcium-release-activated calcium (CRAC) channels to treat inflammatory diseases.
• Capstan Therapeutics: Develops personalised cell therapies using proprietary engineering technologies.
• Caris Life Sciences: Provides comprehensive molecular profiling for oncology, enabling personalised cancer treatment.
• Carrot: A digital health company that offers smoking cessation programmes supported by data-driven interventions.
• Cellipont Bioservices: Provides cell therapy manufacturing and development services for advanced therapeutics.
• Charm Therapeutics: Utilises deep learning for the discovery and development of cancer therapies.
• Chemomab Therapeutics: Develops monoclonal antibody therapies for rare fibrotic and inflammatory diseases.
• Compass Therapeutics: Focuses on next-generation antibody therapeutics for cancer and autoimmune diseases.
• Congruence Therapeutics: Develops therapies for rare diseases caused by protein misfolding.
• Convergent Therapeutics: Creates innovative radiopharmaceuticals for the treatment of prostate cancer.
• Corteria Pharmaceuticals: Develops treatments for cardiopulmonary diseases, focusing on improving patient outcomes.
• Corvus Pharmaceuticals: Focuses on immuno-oncology and immunotherapy to treat a variety of cancers.
• Credit Pharma: Provides financing solutions to healthcare companies by monetising intellectual property and royalty streams.
• Crinetics Pharmaceuticals: Develops small molecule therapeutics for rare endocrine diseases.
• Cyrus Biotechnology: Utilises computational biology to develop biologic drugs with improved properties.
• Dami & Xiaomi: Provides healthcare services and products, focusing on the Chinese market.
• Dehan Dental Clinic: Offers specialised dental care and services in China.
• Delfi Diagnostics: Develops liquid biopsy technologies for the early detection of cancer.
• DIH: Specialises in robotic rehabilitation and digital healthcare solutions for medical institutions.
• Disc Medicine: Focuses on therapies for blood diseases, targeting iron homeostasis in the body.
• DLAB: Provides digital healthcare solutions to improve patient care and clinical workflows.
• EC Healthcare: Offers healthcare services across Hong Kong and China, including medical and wellness solutions.
• Edding Group: Focuses on the development of innovative biopharmaceutical products in China.
• Edgewise Therapeutics: Develops small molecule therapies for serious muscle diseases.
• Electra Therapeutics: Focuses on immunotherapies for treating autoimmune diseases and cancer.
• Enliven Therapeutics: Develops targeted cancer therapies using precision medicine approaches.
• Enterome: Utilises microbiome-based drug discovery to develop therapies for cancer and inflammatory diseases.
• Enyo Pharma: Develops small molecule drugs targeting viral infections and liver diseases.
• Epigenic Therapeutics: Focuses on developing gene therapies that address epigenetic alterations in diseases.
• Ethris: Develops mRNA therapeutics for treating respiratory diseases and other conditions.
• Eurolife Healthcare: Provides a range of pharmaceutical products and services to global markets.
• Evox Therapeutics: Develops exosome-based therapies for rare and severe diseases.
• Evozyne: Utilises synthetic biology to design proteins for therapeutic and industrial applications.
• Fore Biotherapeutics: Focuses on precision oncology therapies for patients with rare genetic mutations.
• ForSight VISION6: Develops ophthalmic devices and treatments to improve vision and treat eye diseases.
• Forward Health: A technology-driven healthcare provider that offers preventive care and primary health services.
• Frontera Therapeutics: Develops gene therapies to treat genetic diseases in underserved patient populations.
• Fusion Pharmaceuticals: Develops targeted alpha therapies to treat cancer, using radiopharmaceuticals.
• FUSmobile: Specialises in developing non-invasive, focused ultrasound therapies for various medical conditions.
• FutuRx: A biotechnology incubator that supports early-stage life sciences companies in Israel.
• Garuda Therapeutics: Focuses on developing off-the-shelf stem cell therapies to treat blood disorders.
• Gaush Meditech: Provides advanced medical devices and diagnostic equipment to healthcare providers in China.
• Gennao Bio: Develops gene therapy solutions for genetic and rare diseases using a proprietary delivery platform.
• GentiBio: Creates engineered regulatory T cells for the treatment of autoimmune and inflammatory diseases.
• GliXogen Therapeutics: Develops small molecule drugs to target specific genetic mutations in cancer.
• Good Doctor Cloud Health: Offers online medical consultations and healthcare services to patients in China.
• Gracell Biotechnologies: Focuses on cell therapies for cancer and autoimmune diseases, with an emphasis on innovation.
• HiRO: Develops digital health solutions that utilise artificial intelligence for better patient management and care.
• Iambic Therapeutics: Focuses on the discovery and development of cancer immunotherapies.
• iECURE: Develops gene-editing therapies to treat rare diseases using in vivo approaches.
• Ikena Oncology: Specialises in developing precision medicines for genetically defined cancers.
• ImmPACT Bio: Creates cell therapies for treating cancer, using a next-generation chimeric antigen receptor (CAR) platform.
• Innvolution Healthcare: Provides innovative medical devices and solutions for cardiovascular and peripheral interventions.
• Insilico Medicine: Utilises artificial intelligence to discover and develop new drugs and therapeutics.
• Insmed: Develops therapies for rare diseases, focusing on serious respiratory conditions.
• InspireMD: Offers advanced technologies for the treatment of vascular and coronary artery diseases.
• InventisBio: Focuses on the research and development of innovative drugs for cancer and metabolic diseases.
• Invivyd: Develops monoclonal antibodies to protect against emerging infectious diseases.
• Janux Therapeutics: Creates targeted cancer therapies using its proprietary therapeutic platforms.
• Jinxin Fuxing Eldercare: Provides senior care services and facilities in China.
• Kapiva: Offers a range of natural health products and supplements based on Ayurvedic principles.
• Kartos Therapeutics: Focuses on developing transformative therapies for haematological cancers.
• Keros Therapeutics: Develops therapies for rare haematological and musculoskeletal disorders.
• Kinnate Biopharma: Develops targeted therapies for cancer patients with genomically defined conditions.
• Koya Medical: Creates wearable devices to treat chronic lymphoedema and other circulatory disorders.
• Kumquat Biosciences: Utilises small molecule immunomodulators to treat cancer and autoimmune diseases.
• Laekna Therapeutics: Develops innovative therapies for cancer and liver diseases, focusing on novel treatment approaches.
• Laxmi Dental: Provides advanced dental care and solutions in India, focusing on oral health.
• Leal Therapeutics: Focuses on the development of CNS therapies for neurodegenerative and psychiatric disorders.
• LifeCell: Develops regenerative medical products and services, including tissue grafts and storage solutions.
• Magenta Medical: Develops advanced solutions for heart failure patients, including mechanical circulatory support devices.
• Marksans Pharma: Manufactures and markets generic pharmaceutical products for various therapeutic areas.
• MBX Biosciences: Develops precision endocrine therapies to address rare hormonal disorders.
• MDClone: Provides data solutions to enable healthcare providers to analyse and share medical information securely.
• Memebox: Offers a range of beauty and skincare products, focusing on personalised beauty experiences.
• MinervaX: Develops vaccines for bacterial infections, with a focus on maternal and neonatal health.
• NeRRe Therapeutics: Focuses on the development of treatments for diseases caused by neuronal hypersensitivity.
• Neurelis: Specialises in therapies for neurological disorders, with a focus on seizure management.
• Neurogastrx: Develops therapies for gastrointestinal disorders using targeted approaches to treatment.
• Neuropace: Offers neuromodulation solutions for the treatment of epilepsy and other neurological disorders.
• NewMed: Provides innovative health solutions, including wearable devices and digital health platforms.
• NextCure: Develops novel immunotherapies for cancer treatment, focusing on overcoming tumour resistance.
• Noctrix Health: Develops neuromodulation devices for the treatment of restless leg syndrome and other conditions.
• Nucleix: Utilises advanced molecular technologies to develop non-invasive diagnostic tests for cancer.
• Odyssey Therapeutics: Focuses on the development of precision medicines for autoimmune diseases and cancer.
• OmniGuide Surgical: Provides surgical tools for minimally invasive procedures in various medical specialities.
• Passage Bio: Develops gene therapies for central nervous system disorders using a proprietary technology platform.
• Pathalys Pharma: Develops therapies to address unmet needs in kidney disease and related conditions.
• Perfuse Therapeutics: Focuses on developing therapies for diseases related to the ocular vascular system.
• PIC Therapeutics: Develops small molecule therapeutics that target cancer at the level of protein translation.
• PMV Pharmaceuticals: Creates precision oncology drugs that target p53 mutations in various cancers.
• Prelude Therapeutics: Focuses on developing targeted therapies for cancer and rare diseases.
• Prothelia: Develops therapies for muscle diseases, including treatments for muscular dystrophy.
• Pulnovo Medical: Focuses on developing interventional devices for the treatment of pulmonary vascular diseases.
• Q32 Bio: Develops therapies to regulate immune pathways for the treatment of severe autoimmune and inflammatory diseases.
• Radius Health: Specialises in developing and commercialising innovative therapeutics for osteoporosis and oncology.
• Rampart Bioscience: Develops therapies that focus on improving mitochondrial function to treat genetic diseases.
• ReCode Therapeutics: Utilises lipid nanoparticles to deliver genetic medicines for respiratory and other diseases.
• ReLIA Therapeutics: Develops RNA-based therapeutics for the treatment of various genetic disorders.
• RePare Therapeutics: Focuses on developing precision oncology therapies that target DNA damage repair.
• Scorpion Therapeutics: Develops targeted therapies to treat cancer by addressing complex oncogenic drivers.
• scPharmaceuticals: Develops innovative solutions to deliver medicines subcutaneously, improving patient experience.
• Scribe Therapeutics: Utilises CRISPR-based gene editing technologies to develop genetic medicines.
• Sikka Software: Provides AI-driven solutions for healthcare and financial industries, focusing on optimising operations.
• Sionna Therapeutics: Focuses on treating cystic fibrosis through novel small molecule therapies.
• Sitala Medicine: Develops innovative therapies for the treatment of chronic and severe inflammatory diseases.
• Sparrow Pharmaceuticals: Creates therapies to mitigate the side effects of steroid medications.
• SpringWorks Therapeutics: Focuses on developing therapies for rare diseases and cancer.
• Star Therapeutics: Develops treatments for rare blood disorders and other haematological conditions.
• Suraksha Pharma: Manufactures and markets pharmaceutical products, focusing on quality and accessibility.
• TandemAI: Utilises computational chemistry and machine learning for drug discovery and development.
• TELA Bio: Develops implantable soft tissue solutions for hernia repair and plastic reconstructive surgery.
• Tergus Pharma: Provides contract development and manufacturing services for topical and transdermal products.
• Terns Pharmaceuticals: Develops treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases.
• Terremoto Biosciences: Focuses on developing targeted small molecules to treat cancer and other diseases.
• Third Harmonic Bio: Develops novel therapies to target allergic and inflammatory diseases.
• TigerConnect: Offers secure messaging and collaboration solutions for healthcare providers to enhance patient care.
• Treeline Biosciences: Focuses on developing targeted therapies for genetically defined cancers.
• Triveni Bio: Develops novel therapeutics to treat rare genetic diseases using innovative approaches.
• Turnstone Biologics: Specialises in oncolytic virus therapies and T-cell therapies to treat solid tumours.
• TytoCare: Provides telehealth solutions that allow remote medical examinations and consultations.
• Upper Bio: Develops gene therapies to treat rare genetic and metabolic diseases.
• Upstream Bio: Focuses on therapies for respiratory and inflammatory diseases, utilising advanced biological research.
• Uquifa: Manufactures active pharmaceutical ingredients (APIs) for the global pharmaceutical industry.
• Valneva SE: Specialises in the development of vaccines for infectious diseases, including emerging threats.
• Vanqua Bio: Develops treatments for neurodegenerative diseases, targeting disease-modifying mechanisms.
• Velsera: Offers solutions to accelerate the development and delivery of precision medicine.
• Verastem Oncology: Focuses on developing and commercialising new therapies for cancer treatment.
• Verrica Pharmaceuticals: Develops therapies for skin diseases, focusing on innovative topical treatments.
• Whale Imaging: Provides advanced imaging solutions for healthcare providers, enhancing diagnostic capabilities.
• X4 Pharmaceuticals: Develops therapies for rare diseases, particularly those involving the immune system.
• Xtant Medical: Offers orthopaedic products and surgical solutions for spinal disorders and related conditions.
• Yangpu Chenxing: Provides comprehensive healthcare services in China, focusing on patient care and clinical excellence.
• Zentera Therapeutics: Develops innovative therapies for cancer and other severe diseases, focusing on unmet medical needs.
• Zion Pharma: Specialises in the development of small molecule therapies for cancer and neurological disorders.
• Zylox-Tonbridge: Provides endovascular interventional devices and solutions for vascular diseases in China.